NCCN VERSION 2 2015

157 / 188

Version 2.2015, 03/11/15 © National Comprehensive Cancer Network, Inc. 2015, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®. MS-82
NCCN Guidelines Index
Breast Cancer Table of Contents
Discussion
NCCN Guidelines Version 2.2015
Breast Cancer
211. Muss HB, Berry DA, Cirrincione CT, et al. Adjuvant chemotherapy
in older women with early-stage breast cancer. N Engl J Med
2009;360:2055-2065. Available at:
.
212. Olivotto IA, Bajdik CD, Ravdin PM, et al. Population-based
validation of the prognostic model ADJUVANT! for early breast cancer.
J Clin Oncol 2005;23:2716-2725. Available at:
.
213. Loprinzi CL, Ravdin PM. Decision-making for patients with
resectable breast cancer: individualized decisions for and by patients
and their physicians. J Natl Compr Canc Netw 2003;1:189-196.
Available at: .
214. Cooke T, Reeves J, Lanigan A, Stanton P. HER2 as a prognostic
and predictive marker for breast cancer. Ann Oncol 2001;12 Suppl 1:23-
28. Available at:
215. Paik S, Bryant J, Park C, et al. erbB-2 and response to doxorubicin
in patients with axillary lymph node-positive, hormone receptor-negative
breast cancer. J Natl Cancer Inst 1998;90:1361-1370. Available at:
216. Paik S, Bryant J, Tan-Chiu E, et al. HER2 and choice of adjuvant
chemotherapy for invasive breast cancer: National Surgical Adjuvant
Breast and Bowel Project Protocol B-15. J Natl Cancer Inst
2000;92:1991-1998. Available at:
.
217. Piccart MJ, Di Leo A, Hamilton A. HER2. a 'predictive factor' ready
to use in the daily management of breast cancer patients? Eur J Cancer
2000;36:1755-1761. Available at:
.
218. Pritchard KI, Shepherd LE, O'Malley FP, et al. HER2 and
responsiveness of breast cancer to adjuvant chemotherapy. N Engl J
Med 2006;354:2103-2111. Available at:
.
219. Thor AD, Berry DA, Budman DR, et al. erbB-2, p53, and efficacy of
adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer
Inst 1998;90:1346-1360. Available at:
220. Dressler LG, Berry DA, Broadwater G, et al. Comparison of HER2
status by fluorescence in situ hybridization and immunohistochemistry
to predict benefit from dose escalation of adjuvant doxorubicin-based
therapy in node-positive breast cancer patients. J Clin Oncol
2005;23:4287-4297. Available at:
.
221. Joensuu H, Kellokumpu-Lehtinen P, Bono P, et al. Adjuvant
docetaxel or vinorelbine with or without trastuzumab for breast cancer.
N Engl J Med 2006;354:809-820. Available at:
.
222. Piccart-Gebhart M, Procter M, Leyland-Jones B, et al.
Trastuzumab after adjuvant chemotherapy in HER2-positive breast
cancer. N Engl J Med 2005;353:1659-1672. Available at:
.
223. Goldhirsch A, Piccart-Gebhart M, Procter M, et al. HERA TRIAL: 2
years versus 1 year of trastuzumab after adjuvant chemotherapy in
women with HER2-positive early breast cancer at 8 years of median
follow up. Cancer Research 2012;72:S5-2. Available at:
eetingAbstracts/S5-2.
224. Romond E, Perez E, Bryant J, et al. Trastuzumab plus adjuvant
chemotherapy for operable HER2-positive breast cancer. N Engl J Med
2005;353:1673-1684. Available at:
.